trial

GlyT-1 Inhibitor Treatment for Refractory Schizophrenia

NCTId NCT01251055
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 40 (actual)
Sponsored by China Medical University Hospital
Primary completion 2013-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
40 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2010-04
Primary completion
2013-10
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
GlyT-1 inhibitor-1

Sponsors

China Medical University HospitalLead Sponsor

Investigators

1
Hsien-Yuan Lane, MD.PhD.Principal Investigator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
GlyT-1 Inhibitor Treatment for Refractory Schizophrenia — primary completion2013-10

Facts & assertions

4 sourced
Enrollment
40
Phase
PHASE2
Primary Completion Date
2013-10
Status
COMPLETED
relationships
The graph out of here
drug
GlyT-1 inhibitor-1
drug
lead_sponsor
China Medical University Hospital
company
indication
Schizophrenia
indication
Treatment Refractory
indication
Schizophrenia
indication
investigator
Hsien-Yuan Lane, MD.PhD.
person